You are here: Industry Insights > Chi-Med

News List

Chi-Med, BeiGene Enter Clinical Collaboration contractpharma
May 27, 2020
Will evaluate combinations of surufatinib and fruquintinib with tislelizumab for multiple solid tumor cancer indications.
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors En-CPhI.CN
October 12, 2019
Innovent Biologics, Inc. and Hutchison China MediTech Limited announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent's Tyvyt® (sintilimab injection) ...
Innovent and Chi-Med expand global collaboration for solid tumor treatment biospectrumasia
October 10, 2019
Preclinical studies have suggested that surufatinib is able to inhibit angiogenesis, block the accumulation of tumor associated macrophages and promote infiltration of effector T cells into tumors, all of which could contribute to improve anti-tumor activ
Chi-Med’s Surufatinib Study Meets Primary Endpoint Early contractpharma
July 04, 2019
Stops Phase III study of surufatinib in advanced neuroendocrine tumors, meeting the primary endpoint of progression free survival.
Chi-Med Files Application to List in Hong Kong, S.A.R., China and Announces Proposed Global Offering Hutchison China MediTech Limited
April 22, 2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients fiercepharma
April 02, 2019
AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med.
Chi-Med announces commercial launch of Elunate biospectrumasia
November 28, 2018
Elunate is for the treatment of patients with metastatic colorectal cancer (CRC) that have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan.
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer fiercepharma
November 19, 2018
Hutchison China MediTech’s Elunate, which recently became the first China-made drug to win a major oncology approval, has flopped in a key non-small cell lung cancer trial.
Chi-Med Initiates a Ph I Trial of HMPL-523 for AML biospectrumasia
October 22, 2018
This study complements the ongoing Phase Ib dose expansion program of HMPL-523 in a broad range of hematological cancers in Australia.
China approves first "Made in China" cancer drug biospectrumasia
September 07, 2018
The colorectal cancer drug developed by Chi-Med are to be marketed in China under the brand name Elunate

Previous page 1 2 Next page